Meredith Cummins, CEO of NeuroEndocrine Cancer Australia, told BioPharmaDispatch that funding for WELIREG would be "life-changing" for patients because it can reduce the size of tumours or stop their growth.
Patients pushing for positive outcome on MSD's therapy for rare disease
April 10, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 4 September
September 4, 2026 - - Podcast -
A three-pronged expansion of Commonwealth reach in therapeutic-goods regulation
September 4, 2026 - - Latest News -
If the government gives itself more power, don't be surprised when they use it
September 4, 2026 - - Latest News -
Medicines Australia calls for doubling of PBS medicines investment
September 4, 2026 - - Latest News -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - - Latest News -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - - Latest News
